LI-LIQUID Solution for oral administration Ref.[7474] Active ingredients: Lithium

Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Rosemont Pharmaceuticals Ltd, Rosemont House, Yorkdale Industrial Park, Braithwaite Street, Leeds, LS11 9XE, UK

Product name and form

Li-Liquid 509mg/5ml Oral Syrup.

Pharmaceutical Form
Solution for oral administration.

Qualitative and quantitative composition

Lithium Citrate Tetrahydrate 509mg/5ml

equivalent to Lithium Ion 5.4mmol
equivalent to Lithium Carbonate 200mg

For the full list of excipients, see section 6.1

Active Ingredient	Description
Lithium	Little is known about the way the lithium ion can modify neurotransmission within the CNS. Many of the proposed mechanisms have suggested an inhibitory effect on components of various neurotransmitter signalling pathways, such as cyclic AMP formation, cyclic GMP formation, G-proteins or inositol phosphate metabolism.

List of Excipients
Citric acid monohydrate Saccharin sodium Sorbitol solution Syrup liquid glucose Propylene glycol Methyl and propyl hydroxybenzoate Colouring E104 Cherry flavour (containing ethanol and propylene glycol) Purified water

Pack sizes and marketing

Bottles: Amber (Type III) glass bottles with capacity of 150ml.

Closures: HDPE EPE wadded, tamper evident, child resistant.

Marketing authorization holder

Rosemont Pharmaceuticals Ltd, Rosemont House, Yorkdale Industrial Park, Braithwaite Street, Leeds, LS11 9XE, UK

Marketing authorization dates and numbers

PL 00427/0074

27 January 1992

Next: Usage >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.